Although extensive research addresses minorities' low participation in clinical research, most focuses almost exclusively on therapeutic trials.
The existing literature mightmaskimportantissues concerning minorities' participation in clinical trials, and minorities might actually be overrepresented in phase I safety studies that require the participation of healthy volunteers.
It is critical to consider the entire spectrum of clinical research when discussing the participation of disenfranchised groups; the literature on minorities' distrust, poor access, and other barriers to trial participation needs reexamination. Minority participation in clinical trials is an important topic in public health discussions because this representation touches on issues of equality and the eliminationofdisparities,whichare core values of the field. ( There is still room for improvement, however, with significant enrollment issues continuing to affect the representation of Hispanics in clinical trials. One report estimated Hispanic representation in NIH studies at 7.6% of all research participants, 3 and a report on industry-sponsored studies found that only 3% of those participants were Hispanic. 4 Increasing the participation of all minorities in clinical trials is critical for the production of knowledge about new therapies because having diverse research participants can improve the generalizability of medicine. Additionally, minority participation in clinical trials is an important topic in public health discussions because this representation touches on issues of equality and the elimination of disparities, which are core values of the field. Despite academic interest in the topic, most of the focus has been on the benefits that minority groups can experience from clinical trial participation. There has been little discussion about the involvement of minorities in higher risk or lower benefit research. Currently, there are no databases aggregating demographic data from all clinical trials--neither those sponsored by NIH nor those sponsored by the pharmaceutical industry. Examining the entire spectrum of clinical research is important because the goals of clinical trials--as well as the benefits and risks--differ according to a novel therapy's stage of development.
Clinical trials generally proceed in 3 phases. Phase I studies are safety studies, used to establish appropriate doses for subsequent clinical testing and to generate data on adverse events. These studies are primarily conducted by using healthy volunteers who derive no direct health benefits from their participation. Phase II studies are designed to provide preliminary information about the efficacy of a new treatment as well as further information about its safety, using a few hundred participants with the targeted disease.
Participants may derive health benefits from phase II studies, but only about one half of investigational therapies are shown to have promise in phase II trials. 5 Phase III clinical trials require several thousand volunteers with the targeted disease, usually involve the randomization of participants into experimental and placebo arms of the study, and can take from 2 to 4 years to complete. These studies measure the efficacy of an investigational treatment and sometimes a comparative benefit. With an 80% success rate, these trials are believed to offer important health benefits to participants.
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Despite the critical differences between study phases--especially between the goals of and types of participants in phase I and phase III studies--discussions about the representation of minorities in clinical trials virtually ignore these distinctions. Most of the literature focuses exclusively on phase III therapeutic trials. As a result, the existing literature may mask important issues concerning minorities' participation in clinical trials. We propose that the representation of minorities in clinical trials changes dramatically when taking a broader view of study participation. Phase I safety studies elicit a different set of findings regarding the representation of minorities in nontherapeutic clinical trials. Most notably, data provided to the authors by industry as part of a larger empirical project suggest that minorities might actually be overrepresented in studies involving healthy volunteers ( The Tuskegee Syphilis Study and other examples of unethical clinical research prompted new federal regulations, including the creation of institutional review boards, which are intended to govern the ethical conduct of research. 9 Underpinning US regulations is the Belmont Report (1979), written by the National
Commission for the Protection of Human Subjects of Biomedical and Behavioral Research in an effort to highlight the principles needed to guide the ethical conduct of human participant research and to protect against tragedies like the Tuskegee Syphilis Study. One of the ethical principles outlined in the Belmont Report is that of justice, which is concerned with the fair distribution of the benefits and burdens of medical research. Yet, even with the federal protections of research participants implemented in the years after publication of the Belmont Report in 1979, minority participation in clinical research has remained low. These low enrollment numbers prompted new legislative initiatives, such as the NIH Revitalization Act of 1993, which has a section titled ''Inclusion of Women and Minorities'' specifically designed to ensure that women and people of color are given appropriate opportunities to participate in clinical trials research. 1 
LITERATURE ON BARRIERS TO CLINICAL TRIAL PARTICIPATION
In response to the changes in the NIH guidelines, research has emerged debating the merits of minority representation in clinical trials and the barriers to the participation of these groups. 7,8,10---22 Common barriers include distrust, provider perceptions, and access to care.
Distrust
A substantial group of scholars has proposed that minorities, particularly African Americans, are distrustful of medical research because of a history of exploitation. 10, 12, 18 Corbie-Smith et al.
interviewed African Americans to delineate their feelings about clinical trials participation. 10 They found that interviewees were afraid that physicians would not be honest with them about the risks associated with a study, and many were afraid of being a guinea pig. In a 2002 follow-up study, Corbie-Smith et al. found that African Americans were more likely than were Whites to believe that physicians would not fully explain the details of research participation. 7 The study also identified African Americans' stronger fears that their physicians would allow them to participate in a study even if serious harm was anticipated, and 1 out of 4 African Americans expressed a high level of distrust in physicians. 7 In a more recent study investigating minority participation in clinical research, Paskett et al. concluded that minority populations commonly cite mistrust of medical research to explain their lack of interest in clinical trials participation. 17 Likewise, Note. The data are from 2 companies' ''active'' participant databases as queried in June 2010. The companies' identities are confidential as part of their participation in a broader, ongoing empirical project. We selected them on the basis of their large participant databases and the high volume of studies they conduct for industry, which makes them representative of phase I trials conducted in the United States. Facilities with smaller databases of participants report similar demographic data.
Freedman interviewed African
American women in an effort to capture and describe their experiences with research and clinical trials and, more generally, the medical establishment. 23 One woman in the study noted,
We have always had a concern about what white people have done to black people. 23(p945) This comment implies that this proposed mistrust extends far beyond medical research to include the effect of slavery and other historical exploitations. 24 
Provider Perceptions
There is also literature that suggests that physician bias, false perceptions, and prejudices surrounding medical decision-making dictate the lower number of minority participants in trials. Research has shown that physicians are less likely to prescribe certain treatments to their minority patients. As an example, Smedley et al. speculated that physicians operate on a cognitive heuristic learned in medical school and residency that brings prior expectations to each individual encounter with their patients. 19 The phy- Perhaps most significant in relation to a discussion of clinical trial participation, van Ryn and Burke also found that physicians are biased concerning who they believe will comply with difficult therapeutic regimens. 26 Their study suggests that physicians believe African Americans are two thirds as likely to be adherent as are their White patients. Of course, participation in clinical trials research can be a rigorous and demanding enterprise. Thus, it holds that one possible explanation for the underrepresentation of minorities is that physicians do not believe that their African American patients will adhere to the prescribed protocol.
Access to Care
An additional argument that warrants acknowledgment is that people of color have historically had poor access to medical care. In fact, some studies indicate that the majority of disenfranchised minorities have access only to providers and hospitals that have limited resources. 27 
MINORITIES' PARTICIPATION IN PHASE I TRIALS
Issues of trust, physician perceptions and biases, and structural issues such as access to health care might factor into the low levels of minority participation in therapeutic clinical trials. However, the literature on minority participation focuses almost exclusively on phase III research. Thus, current investigations ignore the participation of minorities as healthy volunteers in important safety testing performed during phase I work. Although it has been an underreported phenomenon with few high-quality publications on the topic, we propose that minorities might be overrepresented in phase I trials, which has different implications for research.
Participation Rates
It is currently difficult to assess precisely the demographics of phase I participants because of the lack of centralized databases containing this type of information across clinical trials. Moreover, few studies report aggregate information about phase I trial participants, and those that do tend to focus on the underrepresentation of women in these early phase studies. 34---36 However, those who work in the industry claim that a high percentage of African Americans participate at phase I facilities in the northeastern United States and that a high percentage of Hispanics participate in the southwestern United States, meaning that these groups are represented in percentages much greater than their representation in the US population.
37---39
In 2009, the representation of African Americans and Hispanics in the US population was 12.4% and 15.8%, respectively. 2 Yet, anecdotal evidence within the industry has put both of these groups at rates closer to 40% of participants each in phase I trials. 37 As part of a larger empirical project on phase I clinical trials in the United States, we obtained demographic data on healthy volunteers from 2 of the largest phase I facilities in the country (out of approximately 40 such clinics): 1 in the Northeast and 1 in the Southwest. These preliminary data evince this demographic pattern of high ethnic and racial minority enrollment (Table 1) . In both facilities, the percentage of minority participants is much greater than that of White volunteers (63.9% compared with 36.1%, respectively). African Americans make up 42.3% of the healthy volunteers in the Northeast and 6.1% in the Southwest, for an average of 22.3% between the 2 facilities. This figure represents nearly double the proportion of African Americans one would expect on the basis of population alone. Hispanics make up 14.5% of the healthy volunteers in the Northeast and 54.9% in the Southwest, for an average of 36.8% between the 2 facilities. This finding means that Hispanics are represented at more than twice the rate expected on the basis of US population statistics and almost 5 times their representation in NIHsponsored phase III studies. We acknowledge that these data are not definitive; nonetheless, they illustrate that minority participation in phase I trials is higher than expected on the basis of US demographic data and their representation in therapeutic trials.
Revisiting the Barriers to Participation
The higher than expected participation of minorities as healthy volunteers in phase I studies indicates that it is necessary to revisit and reevaluate the proposed barriers to their participation. Specifically, examining phase I trials puts in doubt the argument about minorities' distrust of medical research. If minorities, especially African Americans, were as distrustful of medical research as the literature suggests, it would not follow that this supposedly underrepresented group would enroll in such high numbers in phase I studies. It would be a paradox for minorities to participate in the riskiest studies and not participate in the studies that could most benefit their medical conditions.
Although the argument that physician bias may contribute to the underrepresentation of minorities in phase III trials is not challenged by the phase I data, there is evidence of an interesting complementary phenomenon that could be occurring. One study found that a phase I facility in the Southwest perceived Hispanic volunteers as more adherent than other groups, and they invested additional resources in hiring Spanish-speaking staff, translating consent forms into Spanish, and recruiting in the Hispanic community to target that group. 37 Moreover, arguments concerning physicians' biases and stereotypes also carry little weight in discussions of phase I trials because of the limited involvement of physician investigators in recruitment. Private sector contract research organizations and pharmaceutical companies' clinical pharmacology units hire large numbers of recruiters and other research staff who recruit, organize, and run most phase I studies. In addition, phase I clinics tend to be located in economically depressed areas of the United States, with a higher concentration of clinics located in the Northeast and in urban areas. 37 These locations tend to facilitate access for racially and ethnically diverse populations.
Financial Incentive to Participate
Additionally, arguments about trust, provider perceptions, and access become more complex when comparing the recruitment of patients for testing the efficacy of a product (phase III) versus the recruitment of healthy volunteers for testing the safety of a product (phase I). A crucial difference between these types of research studies is that volunteers are usually paid large sums for their participation in phase I trials. 39, 40 Hence, arguments about altruistic notions that may be relevant to phase III research are much less applicable to phase I volunteers' motivations. This becomes particularly pertinent when considering that many phase I participants use trials as a major source of income. In fact, there are people who have made a career of participating in phase I clinical trials. 41 Critics have commented that the financial remuneration has led to the creation of a profession, that of the guinea pig. 42, 43 Whereas phase III trial participants have cited fear of being a guinea pig, 10 phase I participants have welcomed this terminology. 44, 45 Because of the loaded nature of the term, however, the US Food and Drug Administration, pharmaceutical companies, and contract research organizations have chosen to refer to these professional volunteers as altruists or independent contractors. 45, 46 
ETHICAL CONSIDERATIONS
The ethical issues associated with phase I trials are also different from those of later phase studies given that healthy volunteers do not experience any health benefits from their participation but do bear a considerable burden of risk. 47 
CONCLUSIONS
Research that promotes a more accurate understanding of minority participation in clinical trials has significant public health implications because it relates to efforts to eliminate disparities and achieve equality through clinical research. Currently, there seems to be an unequivocal belief that participation in clinical studies is both necessary and beneficial for minority populations. We assert that this is an overly simplistic view. Instead, the participation of minorities in clinical trials should be framed in 2 ways. First, individuals of diverse ethnic and racial backgrounds should have the opportunity to participate in clinical trials. This is important from the perspective of fairness, and diversifying participants in clinical trials leads to better science and creates the potential to reduce health disparities in medicine. Second, medical research must not unduly burden or exploit particular groups in society. Regardless of the reasons for the overrepresentation of minorities in phase I trials and the continued underrepresentation of minorities in phase III trials, we need to consider these phenomena from an ethical standpoint. Minorities share a disproportionately greater risk and enjoy disproportionately fewer benefits (from a health and disease standpoint) from participating in clinical trials. If we as a research community are genuinely concerned about the legacies of exploiting minorities for the sake of medical progress, we should question the current system of phase I testing that could lead marginalized communities to believe even more that the research community treats their members as human guinea pigs that fill a particular need in the global economy. 53 
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